The infectious risks in blood transfusion as of today – A no black and white situation

Alter, 2008, The hazards of blood transfusion in historical perspective, Blood, 112, 2617, 10.1182/blood-2008-07-077370

Lefrère, 2013, Arnault Tzanck (1886–1954), founder of the first blood centre worldwide, J Med Biogr, 21, 211, 10.1177/0967772013479270

Kleinman, 2009, Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion, Transfusion, 49, 2454, 10.1111/j.1537-2995.2009.02322.x

Garraud, 2006, Transfusion-transmitted parasitic diseases or transfusion-transmitted parasites? Not just a matter of semantics, Vox Sang, 91, 349, 10.1111/j.1423-0410.2006.00838.x

Siblini, 2002, Reduction of Yersinia enterocolitica load in deliberately inoculated blood: the effects of blood prestorage temperature and WBC filtration, Transfusion, 42, 422, 10.1046/j.1525-1438.2002.00066.x

Altfeld, 2015, Innate immunity against HIV-1 infection, Nat Immunol, 16, 554, 10.1038/ni.3157

Bolton-Maggs, 2013, Serious hazards of transfusion (SHOT) haemovigilance and progress is improving transfusion safety, Br J Haematol, 163, 303, 10.1111/bjh.12547

Zimring, 2015, Pathobiology of transfusion reactions, Annu Rev Pathol, 10, 83, 10.1146/annurev-pathol-012414-040318

Benjamin, 2014, The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines, Transfus Med Rev, 28, 61, 10.1016/j.tmrv.2014.01.001

Tagny, 2009, Characteristics of blood donors and donated blood in sub-Saharan Francophone Africa, Transfusion, 49, 1592, 10.1111/j.1537-2995.2009.02137.x

Tagny, 2008, Blood safety in Sub-Saharan Africa: a multi-factorial problem, Transfusion, 48, 1256, 10.1111/j.1537-2995.2008.01697.x

Bloch, 2012, Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges, Transfus Med Rev, 26, 164, 10.1016/j.tmrv.2011.07.006

Laperche, 2014, [Relevance of safety measures to avoid HTLV transmission by transfusion in 2014], Transfus Clin Biol, 21, 167, 10.1016/j.tracli.2014.07.003

Laperche, 2015, [Blood transfusion: control of infectious risks], Presse Med, 44, 189, 10.1016/j.lpm.2014.06.034

Dodd, 2015, Keeping blood transfusion safe from West Nile virus: American Red Cross experience, 2003 to 2012, Transfus Med Rev, 29, 153, 10.1016/j.tmrv.2015.03.001

Pozzetto, 2015, Is transfusion-transmitted dengue fever a potential public health threat?, World J Virol, 4, 113, 10.5501/wjv.v4.i2.113

Fredericks, 2014, The burden of dengue and chikungunya worldwide: implications for the southern United States and California, Ann Global Health, 80, 466, 10.1016/j.aogh.2015.02.006

Yoon, 2015, High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines, Plos Negl Trop Dis, 9, e0003764, 10.1371/journal.pntd.0003764

Fuller, 2012, The ecology of emerging infectious diseases in migratory birds: an assessment of the role of climate change and priorities for future research, Ecohealth, 9, 80, 10.1007/s10393-012-0750-1

Mackenzie, 2009, The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses, Zoonoses Public Health, 56, 338, 10.1111/j.1863-2378.2008.01208.x

Salvador, 2015, Entry routes for Zika virus in Brazil after 2014 World Cup: new possibilities, Travel Med Infect Dis

Barlet, 2011, [Technological evolutions in blood donation screening and their impact on the residual risk], Transfus Clin Biol, 18, 292, 10.1016/j.tracli.2011.02.025

Tayou Tagny, 2010, The blood donor in Sub-Saharan Africa: a review, Transfus Med, 20, 1, 10.1111/j.1365-3148.2009.00958.x

Cable, 2013, Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review, Vox Sang, 104, 93, 10.1111/j.1423-0410.2012.01640.x

Liumbruno, 2015, Solvent/detergent-treated plasma: a tale of 30 years of experience, Expert Rev Hematol, 8, 367, 10.1586/17474086.2015.1016906

Seltsam, 2013, Update on the use of pathogen-reduced human plasma and platelet concentrates, Br J Haematol, 162, 442, 10.1111/bjh.12403

Prudent, 2014, Proteome changes in platelets after pathogen inactivation – an interlaboratory consensus, Transfus Med Rev, 28, 72, 10.1016/j.tmrv.2014.02.002

Heddle, 2014, Implementation and public acceptability: lessons from food irradiation and how they might apply to pathogen reduction in blood products, Vox Sang, 107, 50, 10.1111/vox.12135

Swissmedic. Rapport d’hémovigilance 2014. http://Swissmedic_Haemo_F.pdf [accessed on December 4th, 2015].

ANSM. Rapport d’activité d’hémovigilance 2014. http://ansm.sante.fr/var/ansm_site/storage/original/application/4ee5a6f35365ab8b2ab1ad5eaccb5bd6.pdf [accessed on December 4th, 2015].

Knutson, 2015, A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment, Vox Sang, 109, 343, 10.1111/vox.12287

Bost, 2015, Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept[™]) over a 5-year period of extensive delivery, Vox Sang, 109, 414, 10.1111/vox.12300

Dasararaju, 2015, Adverse effects of transfusion, Cancer Control, 22, 16, 10.1177/107327481502200104

Garraud, 2015, [Blood transfusion and inflammation as of yesterday, today and tomorrow], Transfus Clin Biol, 22, 168, 10.1016/j.tracli.2015.03.005

West, 2013, Transfusion-related acute lung injury: advances in understanding the role of proinflammatory mediators in its genesis, Expert Rev Hematol, 6, 265, 10.1586/ehm.13.31

Poles D, Watt A. Dawe M, Bolton-Maggs BHB. Haemovigilance reporting in the UK 2013: collaboration to reduce confusion. http://www.shotuk.org/wp-content/uploads/2014-BBTS-Poster-Haemovigilance-Reporting-in-the-UK-2013-collaboration-to-reduce-confusion.pdf [accessed on December 4th, 2015].

Motayo, 2015, Seroprevalence of transfusion transmissible infections (TTI), in first time blood donors in Abeokuta, Nigeria, Afr Health Sci, 15, 19, 10.4314/ahs.v15i1.3

Bloch, 2015, The impact of human immunodeficiency virus infection on obstetric hemorrhage and blood transfusion in South Africa, Transfusion, 55, 1675, 10.1111/trf.13040

Mutocheluh, 2014, Risk factors associated with hepatitis B exposure and the reliability of five rapid kits commonly used for screening blood donors in Ghana, BMC Res Notes, 7, e873, 10.1186/1756-0500-7-873

Pruett, 2015, The use of rapid diagnostic tests for transfusion infectious screening in Africa: a literature review, Transfus Med Rev, 29, 35, 10.1016/j.tmrv.2014.09.003

Rufai, 2014, The prevalence of hepatitis B virus E antigen among Ghanaian blood donors, Pan Afr Med J, 17, e53, 10.11604/pamj.2014.17.53.3390

Mavenyengwa, 2014, Prevalence of human immunodeficiency virus, syphilis, hepatitis B and C in blood donations in Namibia, BMC Public Health, 14, e424, 10.1186/1471-2458-14-424

Kabinda, 2014, Factors for viral infection in blood donors of South Kivu in the Democratic Republic of Congo, Pan Afr Med J, 19, e385, 10.11604/pamj.2014.19.385.4328

Allain, 2011, Challenges in hepatitis B infection among blood donors, Curr Opin Hematol, 18, 461, 10.1097/MOH.0b013e32834bac10

Mbanya, 2005, Blood safety begins with safe donations: update among blood donors in Yaoundé, Cameroon, Transfus Med, 5, 395, 10.1111/j.1365-3148.2005.00608.x

Lefrère, 2011, Estimate of the residual risk of transfusion-transmitted human-immunodeficiency virus infection in sub-Saharan Africa: a multinational collaborative study, Transfusion, 51, 486, 10.1111/j.1537-2995.2010.02886.x

WHO. Making safe blood available in Africa – statement by Dr Neelam Dhingra. http://www.who.int/bloodsafety/en/ [accessed on December 2nd, 2015].

WHO. Universal access to safe blood transfusion. Scaling up the implementation of the WHO strategy for blood safety and availability for improving patient health and saving lives. http://www.who.int/bloodsafety/StrategicPlan2008-2015AccessSafeBloodTransfusion.pdf?ua=1 [accessed on December 2nd, 2015].

WHO 2013: global consultation on hemovigilance, Dubai, November 2012. http://www.who.int/bloodsafety/haemovigilance/haemovigilance-report.pdf [accessed on December 4th, 2015].

Pitman, 2015, Blood component use in a sub-Saharan African country: results of a 4-year evaluation of diagnoses associated with transfusion orders in Namibia, Transfus Med Rev, 29, 45, 10.1016/j.tmrv.2014.11.003

Tagny, 2015, Whole blood pathogen reduction: which benefit for blood safety in Africa?, Int J Hematol Res, 1, 27

Owusu-Ofori, 2015, Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage, Shock, 44, 33, 10.1097/SHK.0000000000000280

Pozzetto, 2011, [Emergent viral threats in blood transfusion], Transfus Clin Biol, 18, 174, 10.1016/j.tracli.2011.01.009

Pozzetto, 2016, [New viral threats in transfusion medicine by 2016], Transfus Clin Biol

Appassakij, 2013, Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat?, Transfusion, 53, 2567, 10.1111/j.1537-2995.2012.03960.x

Valença-Barbosa, 2015, Molecular identification of food sources in triatomines in the Brazilian Northeast: roles of goats and rodents in chagas disease epidemiology, Am J Trop Med Hyg, 93, 994, 10.4269/ajtmh.15-0156

Tseroni, 2015, Prevention of malaria resurgence in Greece through the Association of mass drug administration (MDA) to immigrants from malaria-endemic regions and standard control measures, Plos Negl Trop Dis, 9, e0004215, 10.1371/journal.pntd.0004215

Goodell, 2014, Costs, consequences, and cost-effectiveness of strategies for Babesia microti donor screening of the US blood supply, Transfusion, 54, 2245, 10.1111/trf.12805

Karafin, 2012, The scientific method at work: xenotropic murine leukemia virus-related virus is neither a cause of chronic fatigue syndrome nor a threat to the blood supply, Transfusion, 52, 222, 10.1111/j.1537-2995.2011.03518.x

Burnouf, 2014, Ebola: a call for blood transfusion strategy in sub-Saharan Africa, Lancet, 384, 1347, 10.1016/S0140-6736(14)61693-7

Millar, 2012, Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products, Br J Haematol, 158, 442, 10.1111/j.1365-2141.2012.09201.x

Martin, 2013, Risk of transmission of Creutzfeldt-Jakob disease via blood and blood products. The French risk-analysis over the last 15 years, Transfus Clin Biol, 20, 398, 10.1016/j.tracli.2013.06.001

Beale, 2011, Is there evidence of recent hepatitis E virus infection in English and North Welsh blood donors?, Vox Sang, 100, 340, 10.1111/j.1423-0410.2010.01412.x

Cleland, 2013, Hepatitis E virus in Scottish blood donors, Vox Sang, 105, 283, 10.1111/vox.12056

Xu, 2013, An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients, Transfusion, 53, 2505, 10.1111/trf.12326

Sauleda, 2015, Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain), Transfusion, 55, 972, 10.1111/trf.12929

Gallian, 2014, [Hepatitis E virus: blood transfusion implications], Transfus Clin Biol, 21, 173, 10.1016/j.tracli.2014.07.007

Slot, 2013, Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012, Euro Surveill, 18, 10.2807/1560-7917.ES2013.18.31.20550

Guo, 2010, Prevalence of hepatitis E virus in Chinese blood donors, J Clin Microbiol, 48, 317, 10.1128/JCM.01466-09

Lapa, 2015, Epidemiology of hepatitis E virus in European Countries, Int J Mol Sci, 16, 25711, 10.3390/ijms161025711

Gallian, 2014, Hepatitis E virus infections in blood donors, France, Emerg Infect Dis, 20, 1914, 10.3201/eid2011.140516

Smith, 2015, Variability and pathogenicity of hepatitis E virus genotype 3 variants, J Gen Virol, 96, 3255, 10.1099/jgv.0.000264

Izopet, 2015, Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France, J Clin Virol, 70, 39, 10.1016/j.jcv.2015.06.103

Lhomme, 2015, Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France, Infect Genet Evol, 35, 50, 10.1016/j.meegid.2015.07.028

Colson, 2015, Hepatitis E virus genotype 4 in Southeastern France: still around, Liver Int

Pillonel, 2014, [Assessment of a transfusion emergent risk: the case of HEV], Transfus Clin Biol, 21, 162, 10.1016/j.tracli.2014.07.004

Gallian, 2014, [Hepatitis E virus: Blood transfusion implications], Transfus Clin Biol, 21, 173, 10.1016/j.tracli.2014.07.007

Andonov, 2014, Serological and molecular evidence of a plausible transmission of hepatitis E virus through pooled plasma, Vox Sang, 107, 213, 10.1111/vox.12156

Hauser, 2014, Hepatitis E transmission by transfusion of Intercept blood system-treated plasma, Blood, 123, 796, 10.1182/blood-2013-09-524348

Sabino, 2012, Human immunodeficiency virus prevalence, incidence, and residual risk of transmission by transfusions at Retrovirus epidemiology donor study-II blood centers in Brazil, Transfusion, 52, 870, 10.1111/j.1537-2995.2011.03344.x

de Almeida-Neto, 2013, Prevalence of serologic markers for hepatitis B and C viruses in Brazilian blood donors and incidence and residual risk of transfusion transmission of hepatitis C virus, Transfusion, 53, 827, 10.1111/j.1537-2995.2012.03840.x

Carneiro-Proietti, 2012, Human T-lymphotropic virus type 1 and type 2 seroprevalence, incidence, and residual transfusion risk among blood donors in Brazil during 2007-2009, AIDS Res Hum Retroviruses, 28, 1265, 10.1089/aid.2011.0143

Noubouossie, 2012, Asymptomatic carriage of malaria parasites in blood in Yaounde, Transfus Med, 22, 63, 10.1111/j.1365-3148.2011.01121.x